Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

LTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Safe Harbor

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of CETHRIN and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.


'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... Fla. , July 29, 2014 /PRNewswire-iReach/ -- ... service provider, has launched its Medical Equipment ...  These services are tailored to the cruise ... standards prompted industry operators to propose that they ... MHG Medical,s new program is intended to create ...
(Date:7/29/2014)... 29, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling ... ways Roche is partnering with customers to redefine the ... us every day that they,re looking for a partner ... their labs and offices," said Jack Phillips , ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Chlorine helps keep ... more likely to develop eye infections, doctors say. ... as well as blurry vision, said Dr. Sampson Davis, ... in New Jersey. It,s important to understand why ... washes away the outer film layer of the eye ...
(Date:7/29/2014)... 29, 2014 The Board of Governors of ... Hart LLP ’s Connie Akridge to serve as ... as President of the Foundation. Akridge served as President of ... a partner at Holland & Hart in Las Vegas, providing ... matters to insurance and healthcare clients for more than 25 ...
(Date:7/29/2014)... 2014 Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... suffered serious liver injuries due to the acetaminophen ... a multidistrict litigation underway in U.S. District Court, ... According to an Order dated July 23rd, the ... bellwether case and discovery issues. Among other things, ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter ... healthy diet and good sleep can protect the body against ... process at a cellular level, researchers report. A study ... linked to increased shortening of telomeres, the protective caps at ... "We found that over a one-year period, the more ...
Breaking Medicine News(10 mins):Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 2Health News:Healthy Habits May Slow Cellular Signs of Aging, Study Finds 3
... As the United States moves toward the goal of ... from the Regenstrief Institute provides a framework for evaluating the ... as the health internet. The study, which appears ... American Medical Informatics Association , also reports on the initial ...
... ... resource deployment through enhanced territory alignment , ... (PRWEB) May 11, 2010 -- The TerrAlign Group, Inc. a ... the inaugural launch of Veeva System’s Veeva Web™ program. Inclusion in this program ...
... So often the rare informs the common. Penn researchers ... have shown that it may be related to epileptic and ... A team of researchers from the University of Pennsylvania School ... professor of Neurology and director of the Penn Epilepsy Center, ...
... Oklahoma, Massachusetts asked to pull back products , TUESDAY, ... E.coli-tainted lettuce expanded late Monday as another food company ... farm currently under investigation by the U.S. Food and ... , According to the Associated Press , California-based ...
... Only ... ... KWizCom, a leading provider of critical SharePoint components to over 3,000 organizations around the ... giant AT&T. KWizCom’s Mobile Extensions , a smart phone connector that permits intelligent, ...
... Canvas Provides Health ... On Mobile Devices. , , ... Herndon, VA (PRWEB) May 11, 2010 -- Canvas announced today it had released ... HITECH compliant mobile applications on the Canvas service. The Health Insurance Portability and ...
Cached Medicine News:Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 2Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 3Health News:TerrAlign Selected to Join Veeva System's Veeva Web Program 4Health News:Rare disease in Amish children sheds light on common neurological disorders 2Health News:Tainted Lettuce Recall Expands 2Health News:Tainted Lettuce Recall Expands 3Health News:KWizCom's Mobile Extensions for SharePoint Receive AT&T Certified Solutions Status 2Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 2Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 3Health News:HIPAA HITECH Compliant Mobile Apps Available for Android, Blackberry and Windows Mobile Smartphones 4
... Spatula Tips That Mimic Corneal Curvature. Designed To ... Created With The IntraLase TMFS Laser System., ... Of The Forceps Are Designed To Facilitate Access ... Achieved, The Cross-Action Forceps Design Allows The Surgeon ...
... Allowing The Exact,Outer Diameter Measurement Of A ... ,Increments.,Easy And Quick To Use, With One-HandedOperation. ... Over A Cornea For Confirmation Of Exact ... ,Guaranteed For ...
... Safely And Easily Cut Foldable Lenses Through ... The Incision., ,Specially Designed To Cut And ... Lenses With Ease With One Instrument., ,Ideal ... Lenses Which Are Damaged, The Wrong Diopter ...
... Gauge Measures 360 Degrees & Can Be ... A Cornea. 7mm Inner Diameter & 14mm Outer ... Only Astigmatism Gauge That Can Be Set For ... Degree Around The Globe., ,Marks Single Or Paired ...
Medicine Products: